logo
Plus   Neg
Share
Email

American Express Reaffirms FY19 Outlook - Quick Facts

While reporting financial results for the second quarter, American Express Co. (AXP) on Friday reaffirmed its earnings and revenue growth guidance for the full-year 2019.

For fiscal 2019, the company continues to project earnings in the range of $7.64 to $8.14 per share and adjusted earnings in the range of $7.85 to $8.35 per share. The company's 2019 revenue growth guidance also remains 8 to 10 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $8.13 per share on revenue growth of 8.0 percent to $43.57 billion for the year. Analysts' estimates typically exclude special items.

Further, the company also plans to continue returning a significant portion of the capital it generates to shareholders and expects to increase the regular quarterly dividend on its common shares outstanding to 43 cents per share from 39 cents beginning with the third quarter 2019, subject to approval by the company's board of directors.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) unveiled a 16-inch MacBook Pro laptop with a larger screen and redesigned keyboard. It is the first major update since the MacBook Pro line was revamped three years ago. The company has moved from a 15-inch screen to a higher-resolution 16-inch screen. Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup.
Follow RTT
>